Aplastic Anemia Market to Witness Significant Growth by 2034, Fueled by Rising Prevalence and a Strong Pipeline
The aplastic anemia treatment market is poised for significant growth, with key pharmaceutical companies including Novartis, Pfizer, Teva Pharmaceuticals, Kyowa Kirin, Regeneron Pharmaceuticals, Gamida Cell, and others leading therapeutic innovation in this rare hematologic disorder.
DelveInsight's " Aplastic Anemia Market Insight, Epidemiology And Market Forecast - 2034" report provides an in-depth understanding of aplastic anemia, including historical and forecasted epidemiology as well as market trends across the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan.
According to the comprehensive analysis, the aplastic anemia market, valued at approximately USD 270 million in 2023 across the 7MM, is projected to expand substantially through 2034, fueled by increasing disease incidence, growing uptake of existing therapies, and the anticipated launch of promising pipeline candidates.
Furthermore, the US currently dominates the aplastic anemia treatment landscape, accounting for approximately 70% of the market share in the 7MM, followed by Japan with the second-highest market value at approximately USD 35 million in 2023. Among European nations, Germany leads the market, with additional growth anticipated across all regions during the forecast period.
Download the Aplastic Anemia Market Forecast Report to understand which factors are driving the Aplastic Anemia market @ Aplastic Anemia Market Trends.
DelveInsight's aplastic anemia epidemiological analysis reveals that Japan reported the highest aplastic anemia incident cases, contributing approximately 30% of cases across the 7MM in 2023. Notably, 56% of aplastic anemia cases were reported in individuals aged 60 and above, while 43% were below the age of 60.
Discover evolving trends in the Aplastic Anemia patient pool forecasts @ Aplastic Anemia Epidemiological Analysis.
The current aplastic anemia treatment varies based on patient age and disease severity. Hematopoietic stem cell transplantation (HSCT) remains the standard of care for patients under 40 years, while immunosuppressive therapy (IST) is preferred for those above 40 years. Novartis' PROMACTA / REVOLADE (eltrombopag) currently leads market revenue, followed by various immunosuppressive therapies. However, younger patients experience significantly better long-term survival compared to those aged 60 and above, highlighting a critical unmet need for improved management strategies in older populations.
The aplastic anemia therapeutic landscape is evolving with several marketed and emerging options. ALVAIZ (eltrombopag choline) from Teva Pharmaceuticals (NYSE: TEVA), an oral thrombopoietin receptor agonist that stimulates platelet production, approved in November 2023, represents an important treatment advancement. In Japan, Kyowa Kirin's ROMIPLATE has gained approval for patients showing inadequate response to conventional therapy.
The patent for PROMACTA (eltrombopag), a key treatment for aplastic anemia, is set to expire on July 13, 2025. This expiry will likely lead to the introduction of generic versions, which can reduce treatment costs and increase patient access. As Promacta is currently a leading therapy in the aplastic anemia market, the availability of generics is expected to intensify competition, lower prices, and potentially shift prescribing patterns.
Looking toward future market growth, promising pipeline candidates include REGN7257 from Regeneron Pharmaceuticals (NASDAQ: REGN), a gamma chain cytokine receptor antibody targeting the common gamma chain found in various interleukin receptors. Currently in Phase I/II clinical trials, this therapy aims to address T-cell-mediated pathogenesis in severe aplastic anemia patients who have relapsed after immunosuppressive therapy. Another noteworthy emerging therapy is OMISIRGE (omidubicel) by Gamida Cell (NASDAQ: GMDA), a nicotinamide-modified allogeneic hematopoietic progenitor cell therapy derived from cord blood.
In April 2025, CK0801, an allogeneic T regulatory (Treg) cell therapy manufactured by Cellenkos, received FDA Orphan Drug Designation for aplastic anemia, supporting its development as a novel treatment for this rare condition. A Phase III registration trial is planned for the second half of 2025, positioning CK0801 as a promising non-immunosuppressive option for aplastic anemia patients unresponsive to standard therapies.
Discover evolving trends in the Aplastic Anemia treatment landscape @ Aplastic Anemia Recent Developments.
Despite therapeutic advances, significant challenges remain in the aplastic anemia treatment landscape. Finding effective and well-tolerated treatments for patients who do not respond to standard therapies or who are unsuitable candidates for aggressive interventions continues to be problematic. Additionally, poor survival rates among older patients represent a substantial unmet medical need requiring innovative approaches.
Table of Contents
1. Key Insights
2. Executive Summary of Aplastic Anemia
3. Aplastic Anemia Competitive Intelligence
4. Aplastic Anemia: Market Overview at a Glance
5. Aplastic Anemia: Disease Background and Overview
6. Patient Journey
7. Aplastic Anemia Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Aplastic Anemia Unmet Needs
10. Key Endpoints of Aplastic Anemia Treatment
11. Aplastic Anemia Marketed Products
12. Aplastic Anemia Emerging Therapies
13. Aplastic Anemia: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Aplastic Anemia
17. KOL Views
18. Aplastic Anemia Market Drivers
19. Aplastic Anemia Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Related Reports
Aplastic Anemia Pipeline Insight
Aplastic Anemia Pipeline Insight provides comprehensive insights about the Aplastic Anemia pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Aplastic Anemia companies, including Gamida-Cell, Regeneron Pharmaceuticals, and BioLineRx, among others.
About DelveInsight
DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
Insider Buying and Options Surge Spark Bullish Interest in UnitedHealth (UNH)
UnitedHealth Group (UNH) is drawing attention from traders after a spike in call option activity and notable insider buying. Despite the stock being down nearly 40% year-to-date, a weaker-than-expected Q1 earnings report, and a softer outlook, recent activity suggests growing confidence in a potential recovery. Confident Investing Starts Here: Heightened Activity Signals Bullish Sentiment On Thursday, more than 162,000 call options were traded on UNH. That's a 29% jump compared to the stock's typical daily call volume of around 126,000. This level of activity often reflects bullish expectations from traders anticipating upward price movement. Insiders are also showing conviction. On May 14, Director John H. Noseworthy purchased 300 shares at an average price of $312.16. Six days later, CEO Stephen Hemsley bought 86,700 shares at an average of $288.57 per share, totaling over $25 million. In total, insiders have acquired 109,408 shares over the past 90 days, worth approximately $31.6 million. Insider buying of this scale often signals confidence in long-term value. Institutional investors have also been increasing their exposure to these assets. Vanguard, Wellington Management, and Norges Bank all added to their positions last quarter. Institutional ownership now stands at 87.9%, highlighting continued support from long-term holders. Stock Rebounds Slightly as Fundamentals Show Mixed Signals The stock closed Friday at $303.22, up 2.49% on the day. It remains far below its 52-week high of $630.73 and just above the recent low of $248.88. At current levels, UNH has a market cap of about $275 billion, a P/E ratio of 14.11, and a dividend yield of 2.84%. The company recently raised its quarterly dividend to $2.21 per share. UnitedHealth posted Q1 revenue of $109.6 billion, slightly below consensus estimates. Earnings per share came in at $7.20, missing expectations of $7.29. While analysts still expect full-year EPS of $29.54, several firms have lowered their price targets in response to the softer results and rising sector concerns. Options market data reinforces the bullish tilt. The put/call ratio is 0.48, indicating more call buying than put buying. This ratio suggests traders are positioning for a potential rebound in the near term. In summary, while UnitedHealth continues to face pressure from weaker earnings and macroeconomic headwinds, the surge in call option activity, insider buying, and strong institutional support indicate renewed investor interest. Is UNH a Good Stock to Buy Right Now? According to The Street's analysts, UnitedHealth is a Moderate Buy. The average UNH price target is $369.73, implying a 21.93% upside. See more UNH analyst ratings Disclaimer & Disclosure Report an Issue
Globe and Mail
an hour ago
- Globe and Mail
Microbot Medical Continues to Strengthen Commercial Capabilities in Preparation for the anticipated Q3 2025 Launch of its LIBERTY® Endovascular Robotic System
HINGHAM, Mass., June 09, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY Endovascular Robotic System, today announced the continued expansion of its commercial team in preparation for the anticipated U.S. launch of the LIBERTY System, which is projected during the third quarter of 2025. The Company remains actively engaged with the U.S. Food and Drug Administration (FDA), with a 510(k) decision now expected during the third quarter of this year. This updated FDA decision timeline remains within the FDA's original scheduled review window and is not expected to affect the Company's planned launch upon clearance. 'Our recent interactions with the FDA have been productive, and we remain confident in the process and outcome,' said Harel Gadot, Chairman, CEO & President. 'We continue to operate with full momentum and position the Company for an anticipated launch during the third quarter of this year, which includes the continued build out of our commercial infrastructure and preparing the organization to deliver on our strategy.' As part of the Company's ongoing launch preparation, it recently expanded its commercial team with the addition of Michael Lytle as the head of Sales Operations & Analytics. Mr. Lytle brings deep experience in sales support, data analysis, and operational excellence. He is expected to play a key role in shaping market intelligence tools and processes to optimize the sales cycle and drive strategic growth. Prior to joining Microbot, Mr. Lytle held increasing leadership roles at ZOLL Cardiac Management Solutions (CMS), a division of ZOLL Medical Corporation, where he supported the rollout of innovative cardiac care technologies. 'We believe that Michael's addition will strengthen our launch readiness plans, and that his expertise will help us target the right markets, allocate resources effectively, and accelerate commercial execution,' concluded Mr. Gadot. The LIBERTY System is currently under FDA review, is not available for sales in the US, and clearance is not guaranteed. About Microbot Medical Microbot Medical Inc. (NASDAQ: MBOT) is a pre-commercial stage medical technology company with a vision to redefine endovascular robotics and improve the quality of care for millions of patients and providers globally. The Company has developed the world's first single-use, fully disposable endovascular robotic system, which aims to eliminate traditional barriers to accessing advanced robotic systems. Further information about Microbot Medical® is available at Safe Harbor Statements to future financial and/or operating results, future growth in research, technology, clinical development, commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as 'will,' 'believes,' 'plans,' 'anticipates,' 'expects' and 'estimates') should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, the Company's need for and ability to obtain additional working capital to continue its transition to a commercially focused company, market conditions, risks inherent in the development and/or commercialization of the LIBERTY® Endovascular Robotic System, uncertainty in the results of regulatory pathways and regulatory approvals, including whether the FDA will timely grant 510(k) clearance to commercially market the LIBERTY® Endovascular Robotic System in the United States if at all, uncertainty resulting from political, social and geopolitical conditions, particularly any changes in personnel or processes or procedures at the FDA and announcements of tariffs on imports into the U.S., disruptions resulting from new and ongoing hostilities between Israel and the Palestinians and other neighboring countries, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical® can be found under the heading 'Risk Factors' in Microbot Medical's periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC's web site at Microbot Medical® disclaims any intent or obligation to update these forward-looking statements, except as required by law
CTV News
2 hours ago
- CTV News
Japan's Osaka Expo temporarily suspends water shows after high levels of bacteria detected
A view of 'Water Plaza' at the site of the World Exposition in Osaka, on June 4, 2025.(Atsuhiro Maeda/Kyodo News via AP) TOKYO — Popular daily fountain shows and a shallow pool area at Expo 2025 in Osaka have been temporarily suspended due to bacterial contamination that required cleaning and safety checks, the event organizers said on Monday. The aquatic show at the Water Plaza has been suspended since June 4 when legionella bacteria of up to 20 times the legal limit was detected in the water, a week after lower levels of contamination had been found. Another water area, called the Forest of Tranquility — a shallow reservoir over 2.3 hectares (5.7 acres) where visitors can soak their feet and relax — has also been closed for cleaning due to the legionella contamination, which can cause pneumonia. The bacteria contamination is the latest problem hitting the Expo site, where swarms of midges have been bothering visitors for weeks. The venue, built on a former industrial waste burial site in the Osaka Bay in western Japan, where methane gas was detected days before the opening in April. The use of insecticides have so far not effectively blocked the midges. Organizers say they now believe the source of the midges is the Water Plaza and that additional measures are under way, such as installing an insect screen. Organizers have also taken anti-bacterial measures at the water areas, including increased sanitation, cleaning drainage pipes and increasing water circulation, to improve water quality at the reservoir and get approval for a reopening from the health authorities. Hiroyuki Ishige, secretary general of the Japan Association for the 2025 World Exposition, said the organizers should have acted more quickly to close down the water area after detecting increased levels of contamination. 'We deeply apologize over the inconveniences we have caused to the visitors who were looking forward to the (water) shows,' Ishige told a media briefing on Monday. Organizers says there has been no reported health issues. The Osaka Expo involves participants from more than 160 countries, regions and organizations who are showcasing their futuristic exhibits. Organizers had expected 28 million visitors through mid-October. Mari Yamaguchi, The Associated Press
